In conclusion, our results suggest there is sufficient evidence that molecular screening of RASA1 and GDF2 will help clinicians provide a more accurate diagnosis for patients presenting with symptoms of HHT who test negative for mutations in ENG, ACVRL1 and SMAD4. This evidence concerns the gene GDF2 and hereditary hemorrhagic telangiectasia.